Navigation Links
FDA: Tortoise, hare, or something else?

6 congressional hearing, Waxman stated, The FDA never required the manufacturer to [conduct] a thorough post-market study of Avandia's heart risks, noting that the FDA requires such safety studies after drugs are approved.

Safety takes a back seat

As pointed out in previous columns, safety has always been a concern ever since Hippocrates laid out the dictum of First, Do N......

Full article >>>
'"/>

Source:wistechnology.com By Dr. Ogan Gurel 06/20/07


Page: 1 2 3 4 5

Related biology technology :

1. This FlashMob is something super
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Tortoise hare something else

(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, The Future of Orphan ... Pipeline Analysis and Reimbursement ,, ... Summary ,, The author has ... Orphan Diseases Therapeutics - Market Forecasts to ...
(Date:12/15/2009)... -- The International Society for Medical Publication Professionals ... continuing to accept abstracts for its 6th Annual ... April 19-21, 2010. This marks the first time ... the organization to submit an abstract to this ... AM EST, January 15, 2010. For submission details, ...
(Date:12/15/2009)... of several innovative new programs to aid cash-strapped entrepreneurs ... climate. The first is aimed at entrepreneurs and ... a period of 6, 12, 18, or 24 months ... The second is aimed at more established businesses and ... 12 month period at discounted rates, and even the ...
(Date:12/14/2009)... Dec. 14 The third edition of ... , published by the Infusion Nurses ... for anthracycline extravasation.(1) Anthracyclines are a group ... epirubicin that have been used in the treatment ... 1970s.(2) ,, According to the INS ...
Breaking Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
... of Healthcare Brings 22 Years of Strategic Experience ... Prolifiq Software, Inc., today announced that Maureen A. ... of healthcare. In this role, Shaffer will lead ... for sales representatives in the increasingly complex regulatory ...
... Statistically Significant Improvement in Overall Survival -- First Active ... to be Presented at Plenary Session at Upcoming AUA ... Today at 9:00 AM ET -SEATTLE, April 14 ... that the pivotal Phase 3 IMPACT study of PROVENGE(R) ...
... 14 BioVex Inc, a company developing next ... infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial ... treated patients with Stage III and Stage IV melanoma had ... with sites in the United Kingdom, Germany and Australia due ...
Other Biology Technology:Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 2Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 2PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 3PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study 4BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4
(Date:12/15/2009)... can look forward to ultra-low powered or self ... mobile phones. This is made possible with power ... critical elements for power optimisation and higher energy ... IC design is the key enabling capability for ... nation in advanced analog and mixed signal design ...
(Date:12/14/2009)... -- Researchers at Rice University and Baylor College of ... be tracked in real time with MRI as it ... fluorescent dye and kills them with heat. The all-in-one ... growing field called "theranostics" that develops technologies physicians can ... procedure. , The research is available online in the ...
(Date:12/14/2009)... study to date of the proteins in a species ... clues to how similar regeneration could be induced in ... at Indiana University-Purdue University Indianapolis and colleagues investigated over ... a type of salamander that has the unique natural ... with the hope that this knowledge will contribute to ...
Breaking Biology News(10 mins):NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3Tracking new cancer-killing particles with MRI 2IUPUI researchers tackle protein mechanisms behind limb regeneration 2NIST Tests Identify IriTech as Iris Recognition Leader 10240 1NIST Tests Identify IriTech as Iris Recognition Leader 10240 2NIST Tests Identify IriTech as Iris Recognition Leader 10240 3Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 1Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 2Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 3Survey finds just 40 percent of adults absolutely certain they will get H1N1 vaccine 58762 4NEDD9 protein supports growth of aggressive breast cancer 58760 1NEDD9 protein supports growth of aggressive breast cancer 58760 2
... Italy and Virginia Tech in the United States have ... for the production xanthurenic acid (XA) in Anopheles gambiae, ... in the sexual reproduction of the malaria parasite (Plasmodium ... of XA could be an avenue for development of ...
... Results from a new, five-year study show that regular use ... breast cancer by up to 71 percent and may offer ... cancers. , The study findings were released today at ... in Washington, D.C. , "We believe this is the ...
... For ants it's a way of life! Scientists at the ... learn how to visually judge the height of horizontal barriers ... down. Tobias Seidl will be presenting his latest research findings ... on Tuesday 4th April. , Desert ants generally scurry around ...
Other Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
...
Biology Products: